elo-3 Antibody

What is ELOVL3 and why are antibodies against it important in research?

ELOVL3 (elongation of very long chain fatty acids protein 3) is a key enzyme in the fatty acid elongation pathway, catalyzing the first and rate-limiting reaction of the four reactions that constitute the long-chain fatty acids elongation cycle. In humans, the canonical protein has 270 amino acid residues and a mass of 31.5 kDa, with subcellular localization in the endoplasmic reticulum (ER) .

ELOVL3 antibodies are important research tools for studying its expression and function in various physiological and pathological processes. These antibodies enable detection and quantification of ELOVL3 protein in different tissues and experimental conditions, facilitating research into fatty acid metabolism, lipid biosynthesis, and related disorders .

What are the common applications for ELOVL3 antibodies in research?

ELOVL3 antibodies are primarily used in the following applications:

• Immunohistochemistry (IHC): To detect ELOVL3 protein expression in tissue sections

• Western Blot (WB): For protein identification and semi-quantitative analysis

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative detection

• Immunoprecipitation: To isolate and concentrate ELOVL3 protein from complex samples

• Immunofluorescence: For subcellular localization studies

These antibodies have been particularly useful in studying ELOVL3 expression patterns across different tissues, with notable expression observed in the testis in humans .

How do I select the appropriate ELOVL3 antibody for my specific experimental needs?

When selecting an ELOVL3 antibody, consider these critical factors:

• Species reactivity: Ensure the antibody recognizes ELOVL3 from your experimental species. ELOVL3 orthologs have been reported in mouse, rat, bovine, frog, chimpanzee, and chicken species .

• Application compatibility: Verify the antibody has been validated for your intended application (IHC, WB, ELISA, etc.)

• Epitope location: Consider whether the epitope is in a conserved or variable region, which affects cross-reactivity.

• Clone type: Monoclonal antibodies offer high specificity for a single epitope, while polyclonal antibodies recognize multiple epitopes.

• Validation data: Review manufacturer-provided validation data and published literature to assess antibody performance.

• Control experiments: Plan appropriate positive and negative controls for your specific experimental design.

Always perform preliminary validation experiments to confirm the antibody works as expected in your specific experimental setup before conducting full-scale experiments.

What are the key considerations for optimizing Western blot protocols using ELOVL3 antibodies?

For optimal Western blot results with ELOVL3 antibodies, consider these method-specific adaptations:

• Sample preparation:

  • Use appropriate lysis buffers containing protease inhibitors to prevent degradation

  • Include phosphatase inhibitors if studying phosphorylation status

  • For membrane proteins like ELOVL3, consider specialized membrane protein extraction methods

• Gel selection and transfer:

  • ELOVL3 (31.5 kDa) typically resolves well on 10-12% SDS-PAGE gels

  • Optimize transfer conditions for this size range (typically 100V for 1 hour or 30V overnight)

• Blocking and antibody incubation:

  • Test both BSA and non-fat milk as blocking agents (5% concentration in TBST)

  • Optimize primary antibody dilution (typically 1:500 to 1:2000)

  • Incubate at 4°C overnight for better signal-to-noise ratio

• Controls:

  • Include positive control (tissue with known ELOVL3 expression, e.g., testis)

  • Include negative control (tissue with minimal ELOVL3 expression)

  • Consider using ELOVL3 knockdown samples as specificity controls

• Signal detection:

  • Choose detection method based on expected expression level (chemiluminescence for moderate-high expression; fluorescence for more precise quantification)

Remember to validate antibody specificity using appropriate controls before proceeding with experimental samples.

How can I optimize immunohistochemistry protocols for ELOVL3 detection in tissue samples?

For successful IHC detection of ELOVL3, follow these methodological considerations:

• Tissue preparation and fixation:

  • Consider that excessive fixation may mask epitopes

  • Test both frozen and formalin-fixed paraffin-embedded (FFPE) samples

  • For FFPE samples, optimize antigen retrieval methods (heat-induced vs. enzymatic)

• Antigen retrieval optimization:

  • Test citrate buffer (pH 6.0) and EDTA buffer (pH 9.0)

  • Optimize heating time (typically 10-20 minutes)

  • Allow gradual cooling to enhance epitope exposure

• Blocking and antibody incubation:

  • Block with 5-10% normal serum from the species of secondary antibody

  • Include avidin/biotin blocking if using biotinylated detection systems

  • Optimize primary antibody concentration (typically 1:100 to 1:500)

  • Extend incubation time (overnight at 4°C) for better sensitivity

• Detection system selection:

  • For low abundance targets, use signal amplification systems (e.g., tyramide signal amplification)

  • For co-localization studies, consider fluorescent secondary antibodies

  • For quantitative analysis, use DAB detection with standardized development times

• Controls:

  • Include positive control tissue (testis recommended for ELOVL3)

  • Include negative controls (primary antibody omission, isotype control)

  • Consider using tissue from ELOVL3 knockout models if available

• Counterstaining:

  • Use light hematoxylin counterstaining to avoid obscuring specific signals

  • For fluorescence, use nuclear counterstains like DAPI

These methodological adaptations should be systematically tested to determine optimal conditions for your specific tissue samples.

How can I validate the specificity of an ELOVL3 antibody for my research?

Robust validation of ELOVL3 antibody specificity requires multiple complementary approaches:

• Genetic approaches:

  • Use ELOVL3 knockout or knockdown models as negative controls

  • RNA interference with siRNAs (like si-713-ELOVL3, si-394-ELOVL3, and si-410-ELOVL3) to reduce ELOVL3 expression

  • Compare antibody signal between wild-type and ELOVL3-depleted samples

• Peptide competition assay:

  • Pre-incubate antibody with excess immunizing peptide

  • Compare signal between blocked and unblocked antibody

  • Specific signals should be abolished by peptide competition

• Expression correlation:

  • Compare antibody-based protein detection with mRNA expression data

  • Concordance between protein and mRNA levels supports specificity

• Multiple antibody validation:

  • Test multiple antibodies targeting different ELOVL3 epitopes

  • Consistent results with different antibodies indicate specificity

• Mass spectrometry confirmation:

  • Perform immunoprecipitation with the antibody

  • Analyze the precipitated proteins by mass spectrometry

  • Confirm presence of ELOVL3 and absence of cross-reactive proteins

• Overexpression studies:

  • Compare antibody signal in control vs. ELOVL3-overexpressing cells

  • Signal should increase proportionally with overexpression

What approaches can be used to study ELOVL3 function using antibody-based techniques?

Several advanced antibody-based approaches can be employed to elucidate ELOVL3 function:

• Proximity ligation assay (PLA):

  • Detect protein-protein interactions involving ELOVL3

  • Identify binding partners in the fatty acid elongation complex

  • Study how these interactions change under different experimental conditions

• Chromatin immunoprecipitation (ChIP):

  • If studying transcriptional regulation of ELOVL3

  • Identify transcription factors binding to the ELOVL3 promoter

  • Analyze epigenetic modifications affecting ELOVL3 expression

• Co-immunoprecipitation (Co-IP):

  • Pull down ELOVL3 and identify interacting proteins

  • Investigate how these interactions change during different metabolic states

  • Connect ELOVL3 to broader signaling networks

• Immunofluorescence colocalization:

  • Analyze subcellular localization in the ER and potential redistribution

  • Investigate colocalization with other fatty acid metabolism enzymes

  • Study trafficking and localization changes under stress conditions

• Functional blocking experiments:

  • If antibodies with neutralizing capacity are available

  • Use to block ELOVL3 function in cell culture experiments

  • Compare with genetic knockdown approaches

These methodological approaches can provide complementary insights into ELOVL3 function beyond simple detection of expression levels.

How do I reconcile contradictory ELOVL3 antibody detection results across different experimental platforms?

When facing contradictory results across different detection platforms, consider these methodological explanations and reconciliation strategies:

• Epitope accessibility differences:

  • Protein denaturation in Western blot vs. native conformation in IHC

  • Solution: Use multiple antibodies targeting different epitopes

  • Perform native and denaturing conditions to compare epitope accessibility

• Post-translational modifications:

  • ELOVL3 undergoes N-glycosylation , which may affect antibody binding

  • Solution: Treat samples with deglycosylating enzymes

  • Compare detection before and after modification-removing treatments

• Isoform specificity:

  • Different antibodies may detect different ELOVL3 isoforms

  • Solution: Check antibody epitope against known isoform sequences

  • Use isoform-specific primers for RT-PCR validation

• Cross-reactivity with other ELOVL family members:

  • ELOVL family members share sequence homology

  • Solution: Perform specificity tests against recombinant ELOVL1-7 proteins

  • Use knockout/knockdown of specific family members to confirm specificity

• Technical variables:

  • Fixation, sample preparation differences between methods

  • Solution: Standardize sample preparation across platforms

  • Test multiple preparation methods to identify optimal protocols

• Quantitative vs. qualitative differences:

  • Western blot and ELISA provide quantitative data

  • IHC provides spatial information but is less quantitative

  • Solution: Use appropriate statistical methods for each data type

  • Integrate findings rather than expecting exact numerical agreement

When reporting contradictory results, clearly document all experimental conditions and propose biological or technical explanations for the observed differences.

How can antibodies help elucidate the structure-function relationship of ELOVL3?

Antibodies can provide valuable insights into ELOVL3 structure-function relationships through these methodological approaches:

• Epitope mapping:

  • Use antibodies recognizing different ELOVL3 domains

  • Compare detection efficiency after site-directed mutagenesis

  • Identify functionally critical regions by correlating antibody binding with enzymatic activity

• Conformation-specific antibodies:

  • Develop antibodies that recognize specific ELOVL3 conformational states

  • Study conformational changes during the catalytic cycle

  • Identify conditions that alter protein conformation

• Post-translational modification detection:

  • Use modification-specific antibodies (phospho, glyco, etc.)

  • Map modification sites and their functional significance

  • Study how modifications change under different metabolic conditions

• Domain-specific functional studies:

  • Generate antibodies against specific ELOVL3 domains

  • Test if these antibodies can modulate enzyme activity in vitro

  • Correlate structural features with functional outcomes

• Evolutionary conservation analysis:

  • Compare antibody reactivity across ELOVL3 orthologs

  • Identify conserved epitopes that may represent functionally critical regions

  • In yeast models, the amino acid sequence 19-26 (LNSSSSCF) is crucial for ELOVL3 function

These approaches can help connect structural features to functional properties, enhancing our understanding of how ELOVL3 catalyzes fatty acid elongation.

What can antibody-based studies reveal about the regulation of ELOVL3 in metabolic pathways?

Antibody-based approaches can reveal crucial insights into ELOVL3 regulation in metabolic pathways:

• Hormonal regulation studies:

  • Testosterone has been shown to inhibit fat deposition by suppressing ELOVL3 expression

  • Use antibodies to track ELOVL3 protein levels after hormone treatment

  • Correlate changes with functional outcomes like lipid accumulation

• Metabolic state correlation:

  • Compare ELOVL3 expression across different nutritional states

  • Analyze post-translational modifications under different metabolic conditions

  • Use phospho-specific antibodies to track signaling events affecting ELOVL3

• Tissue-specific expression patterns:

  • Map ELOVL3 expression across tissues using antibody-based techniques

  • Correlate expression patterns with tissue-specific lipid profiles

  • Identify cell types with highest expression using co-staining techniques

• Subcellular dynamics:

  • Track ELOVL3 localization changes during metabolic stress

  • Analyze protein stability and turnover rates using pulse-chase experiments

  • Identify factors that influence ELOVL3 trafficking within cells

• Pathway interaction mapping:

  • Use antibody arrays to analyze multiple components simultaneously

  • Perform co-immunoprecipitation to identify interaction partners

  • Study how pathway interactions change in different metabolic states

By implementing these methodological approaches, researchers can build comprehensive models of ELOVL3 regulation in diverse metabolic contexts.

How can antibody engineering techniques be applied to develop improved ELOVL3 research tools?

Recent advances in antibody engineering offer opportunities to develop enhanced ELOVL3 research tools:

• AI-guided antibody design:

  • AI-based technologies for de novo generation of antigen-specific antibody sequences

  • Use germline-based templates to design ELOVL3-specific binding domains

  • Apply computational approaches to mimic natural antibody generation while bypassing its complexity

• Recombinant antibody fragments:

  • Generate single-chain variable fragments (scFvs) against ELOVL3

  • Create smaller antigen-binding fragments (Fabs) for improved tissue penetration

  • Design bispecific antibodies to simultaneously target ELOVL3 and interacting proteins

• Intrabodies and nanobodies:

  • Develop intracellular antibodies (intrabodies) that function within living cells

  • Create camelid-derived single-domain antibodies (nanobodies) for specialized applications

  • These smaller antibody formats may access epitopes unavailable to conventional antibodies

• Fc engineering approaches:

  • Similar to approaches used with elotuzumab, create variants with modified Fc regions

  • Generate non-fucosylated versions for enhanced binding properties

  • Create Fc mutants that eliminate unwanted effector functions

• Site-specific conjugation:

  • Develop ELOVL3 antibodies with precisely positioned reporter molecules

  • Create homogeneous antibody-drug conjugates for targeted delivery

  • Use click chemistry for modular functionalization of antibodies

These advanced engineering techniques can address current limitations in ELOVL3 research tools and enable novel experimental approaches.

What role might ELOVL3 and associated antibodies play in understanding telomere biology and aging?

Research in yeast models has revealed intriguing connections between ELOVL3, telomere biology, and aging that may have broader implications:

• ELOVL3-telomere length relationship:

  • In yeast, deletion of ELO3 decreases telomere length by approximately 100-110 bp

  • Telomere shortening correlates with accelerated chronological aging and reduced replicative lifespan

  • Reconstitution of wild-type ELO3 expression can reverse telomere shortening

• Methodological approaches to study this relationship:

  • Use antibodies to track ELOVL3 expression during cellular senescence

  • Correlate ELOVL3 levels with telomere length in different cell types

  • Apply ChIP techniques to study telomere-associated proteins in ELOVL3-deficient cells

• Mechanistic investigations:

  • ELOVL3 and YKU70/80 appear to share a common pathway for telomere length regulation

  • Deletion of ELO3 affects binding and protection of telomeres by Ku70/80

  • Antibody-based approaches can help elucidate these protein-protein interactions

• Pathway integration:

  • The deletion of KCS1 (an inositol hexakisphosphate kinase) recovers telomere binding function

  • Suggests connections between VLCFA synthesis, inositol phosphate metabolism, and telomere regulation

  • Immunoprecipitation studies can help map these interaction networks

• Translational relevance:

  • Investigate if similar mechanisms exist in mammalian cells

  • Study correlations between ELOVL3 expression and aging markers in human cells

  • Develop antibody panels to simultaneously monitor multiple components of these pathways

This emerging research area suggests ELOVL3 may have functions beyond fatty acid metabolism that influence cellular aging processes.

What are common pitfalls in ELOVL3 antibody-based experiments and how can they be addressed?

Researchers should be aware of these common methodological challenges and their solutions:

• Non-specific binding:

  • Cause: Insufficient blocking or antibody cross-reactivity

  • Solution: Optimize blocking conditions (test different blockers and concentrations)

  • Validation: Perform peptide competition assays and use ELOVL3 knockdown controls

• Inconsistent signal intensity:

  • Cause: Variability in sample preparation or antibody performance

  • Solution: Standardize protein extraction protocols and use internal loading controls

  • Validation: Run titration curves to ensure detection in the linear range

• Post-translational modification interference:

  • Cause: Modifications at or near the epitope affecting antibody binding

  • Solution: Test multiple antibodies targeting different epitopes

  • Validation: Treat samples with modification-removing enzymes (phosphatases, glycosidases)

• ELOVL family cross-reactivity:

  • Cause: Sequence homology between ELOVL family members

  • Solution: Validate antibody specificity against recombinant ELOVL proteins

  • Validation: Include samples with known expression profiles of different ELOVL proteins

• Inadequate controls:

  • Cause: Insufficient validation of antibody specificity

  • Solution: Include positive controls (tissues with known ELOVL3 expression)

  • Validation: Use genetic approaches (knockout/knockdown) for definitive specificity testing

• Subcellular localization artifacts:

  • Cause: Fixation or permeabilization affecting epitope accessibility

  • Solution: Test multiple fixation and permeabilization protocols

  • Validation: Compare results with live-cell imaging using fluorescent protein fusions

Addressing these methodological challenges is essential for generating reliable and reproducible ELOVL3 research data.

How should researchers interpret quantitative data from ELOVL3 antibody-based assays?

Proper interpretation of quantitative ELOVL3 antibody data requires careful consideration of these methodological principles:

• Dynamic range limitations:

  • Western blot has limited quantitative range (typically 2-20 fold differences)

  • ELISA provides more accurate quantification over wider ranges

  • Solution: Match detection method to expected expression differences

• Normalization strategies:

  • For Western blot: Normalize to housekeeping proteins or total protein stains

  • For IHC: Use standardized scoring systems and blinded assessment

  • For ELISA: Include standard curves with recombinant protein

• Statistical analysis considerations:

  • Perform power analysis to determine appropriate sample sizes

  • Use appropriate statistical tests based on data distribution

  • Consider biological vs. technical replicates in analysis

• Absolute vs. relative quantification:

  • Clearly distinguish between relative changes and absolute amounts

  • For absolute quantification, use purified recombinant ELOVL3 standards

  • Report fold-changes with confidence intervals

• Integrating data across methods:

  • Different techniques may give apparently contradictory results

  • Western blot shows total protein while IHC provides spatial information

  • Integrate multiple methods to build comprehensive understanding

• Reporting standards:

  • Clearly document antibody sources, catalog numbers, and dilutions

  • Report detailed methodological parameters for reproducibility

  • Include all controls and validation experiments in publications

Following these methodological guidelines will enhance the reliability and interpretability of quantitative ELOVL3 data.

How might ELOVL3 antibodies contribute to understanding metabolic disorders and potential therapeutic approaches?

ELOVL3 antibodies can facilitate research into metabolic disorders through these innovative approaches:

• Diagnostic biomarker development:

  • Develop sensitive ELISA methods to quantify ELOVL3 in clinical samples

  • Investigate correlations between ELOVL3 levels and metabolic health parameters

  • Create antibody panels to simultaneously assess multiple fatty acid metabolism enzymes

• Therapeutic target validation:

  • Use antibodies to confirm ELOVL3 expression in target tissues

  • Develop blocking antibodies to modulate ELOVL3 function

  • Create antibody-drug conjugates for targeted therapy approaches

• Hormonal regulation mechanisms:

  • Testosterone has been shown to inhibit fat deposition by suppressing ELOVL3 expression

  • Use antibodies to track ELOVL3 levels in response to hormone treatments

  • Investigate sex-specific differences in ELOVL3 expression and function

• Tissue-specific metabolic adaptations:

  • Map ELOVL3 expression across tissues in health and disease

  • Correlate with tissue-specific lipid profiles

  • Identify compensatory mechanisms in ELOVL3-deficient states

• Cellular stress responses:

  • Analyze ELOVL3 regulation during metabolic stress conditions

  • Investigate potential roles in ER stress and unfolded protein response

  • Develop antibodies against stress-induced modified forms of ELOVL3

These research directions highlight the potential contributions of ELOVL3 antibodies to understanding and addressing metabolic disorders.

What techniques can combine ELOVL3 antibodies with other research tools for comprehensive pathway analysis?

Integrating ELOVL3 antibodies with complementary techniques enables powerful pathway analyses:

• Multi-omics integration approaches:

  • Combine antibody-based proteomics with lipidomics

  • Correlate ELOVL3 protein levels with fatty acid profiles

  • Integrate with transcriptomics to study regulatory networks

• CRISPR-based functional genomics:

  • Generate ELOVL3 knockout or knockin cell lines

  • Use antibodies to validate editing efficiency

  • Apply CRISPRi/CRISPRa for nuanced modulation of ELOVL3 expression

• Spatial transcriptomics-proteomics integration:

  • Combine in situ hybridization with immunohistochemistry

  • Map ELOVL3 protein and mRNA distribution in tissues

  • Reveal post-transcriptional regulation mechanisms

• Live cell imaging techniques:

  • Use antibody fragments for live cell tracking

  • Apply FRET-based biosensors to monitor protein-protein interactions

  • Track ELOVL3 dynamics in response to metabolic stimuli

• High-content screening platforms:

  • Develop antibody-based high-throughput screening assays

  • Identify compounds that modulate ELOVL3 expression or activity

  • Screen for factors affecting ELOVL3 subcellular localization

These integrated approaches leverage the specificity of antibodies while overcoming their limitations through complementary technologies, enabling comprehensive pathway analysis.